Sofregen Medical, Inc., a Boston, MA-based early stage medical device company, raised $8m in Series B funding.
The round was led by Anzu Partners from its second venture capital fund focused on breakthrough technologies.
The company intends to use the funds to accelerate the development of its technology and to support the commercialization and availability of Silk Voice™, a U.S. Food and Drug Administration (FDA)-cleared silk protein treatment for vocal fold medialization and vocal fold insufficiency.
Led by Jonathan T. Hartmann, Chief Executive Officer, and Anh Hoang, Co-founder and Chief Science Officer, Sofregen has advanced soft tissue engineering with an advanced platform based on silk protein, also known as fibroin, which has been shown to have unique properties for tissue support and regeneration. Silk Voice is carefully engineered to match the biomechanics of soft tissue for immediate bulking and long-term tissue replacement.
Sofregen also announced that it has appointed Philippe Schaison to its Board of Directors. Dr. Schaison previously served as the CEO, North American of Syneron Candela and President, U.S. Aesthetic & Dermatology at global pharmaceutical company Allergan.